World Health Organization Issues Warning Over Severe Lack of Obesity Medications
Under 10% of individuals that would benefit from obesity jabs including Wegovy can access them, caution the global health agency as it publishes its first recommendations on the medications.
With in excess of 1,000,000,000 individuals worldwide now classified as obese, it is advocating for increased and just availability to these injectable treatments.
Per estimates, more than two billion will be living with obesity by 2030 if no action is taken.
"Our latest guidelines affirms that obesity is a chronic disease that can be managed with thorough and lifelong care," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are significant hurdles to universal availability to the injections that can assist patients in reducing considerable weight, explains the agency.
Weight-Loss Drug Scarcity
Despite the current most favorable outlook, the production of such drugs could only cover around 100 million people – fewer than 10% of the global need, per the health organization.
The guideline urges countries and companies to widen availability, through strategies such as licensing agreements.
A patent on a key compound – the main ingredient of the drug Wegovy – is due to expire in several countries in 2026.
The Way Weight-Loss Jabs Function
These medications replicate a biological compound to slow digestion, reduce hunger and increase satiety so individuals eat less.
People usually see weight reduction after several weeks of beginning the regular doses.
Research indicates patients may regain a significant portion within a year of halting the drug, as their typical hunger come back.
To be overweight or obese increases your risk for experiencing health problems, including type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity concerns individuals in countries worldwide and was linked to 3.7 million fatalities worldwide in 2024, per the WHO.
